Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932.
Anne L AngiolilloReuven J SchoreJohn A KairallaMeenakshi DevidasKaren R RabinPatrick Zweidler-McKayMichael J BorowitzBrent L WoodAndrew J CarrollNyla A HeeremaMary V RellingJohann HitzlerAshley R LaneKelly W MaloneyCindy WangMylène BassalWilliam L CarrollNaomi J WinickElizabeth A RaetzMignon L LohStephen P HungerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
The 0NCI-SR AR B-ALL who received VCR/DEX12 had outstanding outcomes despite receiving one third of the vincristine/dexamethasone pulses previously used as standard of care on Children's Oncology Group (COG) trials. The higher starting dose of MTX of 40 mg/m2/week did not improve outcomes when compared with 20 mg/m2/week. The decreased frequency of vincristine/dexamethasone pulses has been incorporated into frontline COG B-ALL trials to decrease the burden of therapy for patients and their families.
Keyphrases
- palliative care
- low dose
- high dose
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- acute myeloid leukemia
- bone marrow
- randomized controlled trial
- type diabetes
- prognostic factors
- adipose tissue
- metabolic syndrome
- peritoneal dialysis
- pain management
- insulin resistance
- placebo controlled
- weight loss